TheEdgeResearch
Home / Stocks / IBOGF

Universal Ibogaine Inc. (IBOGF)

OTC Healthcare Biotechnology
$0.02 ▲ +0.00%
Market Cap
$7.5M
Sector
Healthcare
Industry
Biotechnology
Beta
4.38
52-Wk Range
0.0023-0.35
CEO
Nicholas Peter Karos
Country
CA
Currency
USD

Universal Ibogaine Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Calgary, AB, CA. The stock last traded at $0.02, up 0.00% on the session, giving a market capitalisation of $7.5M. On trailing twelve-month figures it carries a trailing P/E of -0.09, a net margin of -980.2%. Its beta of 4.38 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.09
Price / Sales
1.46
Price / Book
0.24
EV / EBITDA
-0.56
Gross margin
100.0%
Operating margin
46.4%
Net margin
-980.2%
Return on equity
Debt / equity
0.44
Current ratio
1.60
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
7
IPO date
2022-03-01
Headquarters
Calgary, AB, CA
About Universal Ibogaine Inc.

Universal Ibogaine Inc., a life sciences enterprise, focuses on developing, acquiring, and operating addiction treatment centers across Canada. The company is additionally preparing to launch clinical trials aimed at researching ibogaine's potential therapeutic applications for addiction. Its principal corporate offices are based in Calgary, Canada.

Comparable companies

Universal Ibogaine Inc. is most often compared with the following Healthcare names:

AAGHADXSAGNPFAPLIFGENPFGRTXHESGNMLSFRNUGFVGLS
More research on IBOGF
IBOGF technical analysis IBOGF TheEdge Score Compare against peers
Open full interactive analysis & DCF →